Drug−Protein Adducts:  An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development

511 indexed citations

Abstract

loading...

About

This paper, published in 2003, received 511 indexed citations. Written by David C. Evans, Alan P. Watt, Deborah A. Nicoll‐Griffith and Thomas A. Baillie covering the research area of Oncology, Pharmacology and Computational Theory and Mathematics. It is primarily cited by scholars working on Pharmacology (287 citations), Molecular Biology (222 citations) and Computational Theory and Mathematics (99 citations). Published in Chemical Research in Toxicology.

Countries where authors are citing Drug−Protein Adducts:  An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development

Specialization
Citations

This map shows the geographic impact of Drug−Protein Adducts:  An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drug−Protein Adducts:  An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drug−Protein Adducts:  An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development more than expected).

Fields of papers citing Drug−Protein Adducts:  An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development

Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of Drug−Protein Adducts:  An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Drug−Protein Adducts:  An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

This paper is also available at doi.org/10.1021/tx034170b.

Explore hit-papers with similar magnitude of impact

Rankless by CCL
2026